3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
CNS
3
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Neoplasms
3
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Lymphoma, Large-Cell, Anaplastic
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms by Histologic Type
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
Radiosurgery
9
Magnetic Resonance Spectroscopy
6
pembrolizumab
4
Radiotherapy
4
Nivolumab
4
Fluorodeoxyglucose F18
4
cabozantinib
3
Specimen Handling
3
Paclitaxel
3
Melphalan
3
Ipilimumab
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Busulfan
3
lenvatinib
2
entrectinib
2
cediranib
2
Thiotepa
2
Sunitinib
2
Radiation
2
Peripheral Blood Stem Cell Transplantation
2
Injections
2
Ifosfamide
2
FAPI-46
2
Etoposide
2
Carboplatin
2
Bone Marrow Transplantation
2
Bevacizumab
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
trioctyl phosphine oxide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
alectinib
×
Genitourinary
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts